Abstract

Sreelekshmi Jayakumar35037, Dana Merin35038, Akshaya Krishna35039, Mahima A35040 and Anila KN35041*

Chronic Myeloid Leukaemia (CML) is a neoplastic disease which offshoot from alterations in the Deoxyribonucleic Acid (DNA) of a specific bone marrow cell. It's a well-known hematopoietic stem cell cancer that accounts for 15%-20% of all adult leukaemia cases.

The review article aimed to provide an overview of approaches for managing the development of CML, along with the treatment concerns for special populations like paediatrics, geriatrics, pregnant and lactating women.

The literature search for the review was conducted in Pub Med, Scopus indexed journals.

Chronic Myeloid Leukaemia is the most enormously studied cancers and the effective therapy with the drugs starts from 1953 with alkylating agent, but the use was reduced due to adverse effects. The Interferon alpha treatment had a primary importance on the outcome of patients with CML before the emergence of Imatinib. Imatinib is a tyrosine kinase inhibitor that was named the "Magical Bullet" because of its ability to treat CML with miraculous results. CML has become a manageable disease due to the clever nature of BCR- ABL targeting drug treatments, which have an average survival rate of more than 90%. With the number of patients achieving molecular full remission, HSCT remains the most successful anti leukemic therapy for CML.